Search - tctmd.com

Displaying 721 - 740 of 1137

Sort: Relevancy | Date

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Sara Takahashi

October 30, 2016

Presentation TCT 2016

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Martin W. Bergmann

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Rachel Neubrander

October 30, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Matthew J. Price

October 30, 2016

Presentation TCT 2016

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Marc Gillinov

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation: Scope of the Problem

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz

October 30, 2016

Presentation TCT 2016

Cases #7 and #8: When LAA closure Was Unsuccessful - Lessons Learned

Presenter: Matthew J. Price, Jason H. Rogers, Petr Neuzil

October 30, 2016

Presentation TCT 2016

Cases #5 and #6: Sheath Selection, Orientation, and Lobe Position to Optimize Occluder Deployment

Presenter: Matthew J. Price, Jason H. Rogers, Ramon Quesada

October 30, 2016

Presentation TCT 2016

Cases #3 and #4: Transseptal Puncture for LAA Closure - When Location Makes a Difference

Presenter: Matthew J. Price, Jason H. Rogers

October 30, 2016

Presentation TCT 2016

Cases #1 and #2: Insights From Baseline Imaging - When to Try and When to Walk Away

Presenter: Matthew J. Price, Jason H. Rogers, Jacqueline Saw

October 30, 2016

Advertisement

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Atrial Fibrillation: Scope of the Problem

Cases #7 and #8: When LAA closure Was Unsuccessful - Lessons Learned

Cases #5 and #6: Sheath Selection, Orientation, and Lobe Position to Optimize Occluder Deployment

Cases #3 and #4: Transseptal Puncture for LAA Closure - When Location Makes a Difference

Cases #1 and #2: Insights From Baseline Imaging - When to Try and When to Walk Away

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content